Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Treasury Shares (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Treasury Shares readings, the most recent being $478419.0 for Q4 2024.

  • On a quarterly basis, Treasury Shares fell 90.0% to $478419.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $478419.0, a 90.0% decrease, with the full-year FY2024 number at $478419.0, down 90.0% from a year prior.
  • Treasury Shares hit $478419.0 in Q4 2024 for Unicycive Therapeutics, down from $4.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $11.9 million in Q2 2023 to a low of $352938.0 in Q1 2023.
  • Median Treasury Shares over the past 4 years was $3.8 million (2023), compared with a mean of $3.6 million.
  • The widest YoY moves for Treasury Shares: up 1255.53% in 2024, down 90.0% in 2024.
  • Unicycive Therapeutics' Treasury Shares stood at $674176.0 in 2021, then crashed by 42.2% to $389676.0 in 2022, then soared by 1127.74% to $4.8 million in 2023, then crashed by 90.0% to $478419.0 in 2024.
  • The last three reported values for Treasury Shares were $478419.0 (Q4 2024), $4.8 million (Q3 2024), and $4.8 million (Q2 2024) per Business Quant data.